You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

48 search results for: disease background

Contributions of Type 2 Cytokines to Chronic Pruritus in AD, PN, and CSU
expert video

Contributions of Type 2 Cytokines to Chronic Pruritus in AD, PN, and CSU

Dermatology
Dr. Elmariah introduces the multiple roles of type 2 cytokines in chronic itch.
View more
Exploring Neurosensitization and Pain in Prurigo Nodularis
expert video

Exploring Neurosensitization and Pain in Prurigo Nodularis

Dermatology
Dr. Gil Yosipovitch explains that patients with PN may experience pain due to neurosensitization.
View more
Novel Treatments for Bullous Pemphigoid
expert video

Novel Treatments for Bullous Pemphigoid

Dermatology
Join Dr. Murell as she shares novel treatments for bullous pemphigoid and how these may help fill current gaps in treatment options.
View more
Etiology and Diagnosis of Bullous Pemphigoid
expert video

Etiology and Diagnosis of Bullous Pemphigoid

Dermatology
Professor Joost Meijer discusses the complex etiology and diagnosis of BP
View more
Diagnosis of Bullous Pemphigoid Interactive Patient Case
interactivity

Diagnosis of Bullous Pemphigoid Interactive Patient Case

Dermatology
An interactive patient case tool involving a deeper dive into assessing clinical presentation when diagnosing bullous pemphigoid (BP)
View more
Explore the Global Burden of Pediatric AD (PEDISTAD)
interactivity

Explore the Global Burden of Pediatric AD (PEDISTAD)

Dermatology
This interactive tool allows you to explore the global burden of AD in pediatric patients <12 years from the PEDISTAD Study.
View more
ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP
expert video

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

Rhinology
Prof. Peter Hellings discusses the interconnection between the pathophysiology, burden and clinical management of uncontrolled and/or severe CRSwNP
View more
Effect of Type 2 Inflammation on Skin Barrier Function in AD​
interactivity

Effect of Type 2 Inflammation on Skin Barrier Function in AD​

Dermatology
Gain insights on how type 2 inflammation affects different aspects of skin barrier function – an interactive educational tool.
View more
Type 2 Inflammation and Neuroimmune Axis Dysregulation in AD, PN, and CSU
expert video

Type 2 Inflammation and Neuroimmune Axis Dysregulation in AD, PN, and CSU

Dermatology
Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.
View more
Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone
expert video

Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone

Dermatology
Dr. Ramien explores how advanced systemic therapies may modify atopic dermatitis pathomechanisms including skin barrier dysfunction, and neuroimmune dysregulation
View more
Learn more about how dysregulated type 2 inflammation contributes to polymorphous lesions and dermal epidermal splitting in bullous pemphigoid
Infographic

Bullous Pemphigoid (BP) Pathophysiology Infographic

Dermatology
A static infographic detailing how autoimmunity and Type 2 inflammation play a critical role in the pathophysiology of Bullous Pemphigoid (BP).
View more
ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?
Podcast

ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?

Dermatology
This podcast episode looks at the epidemiology, clinical presentation and classification of atopic dermatitis of the hand and feet and the impact it has on patients' quality of life.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: TaiwanChange country/region